This company listing is no longer active
YGEN Stock Overview
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Yourgene Health Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0052 |
| 52 Week High | UK£0.057 |
| 52 Week Low | UK£0.0019 |
| Beta | 0.86 |
| 1 Month Change | 5.10% |
| 3 Month Change | 139.53% |
| 1 Year Change | -90.89% |
| 3 Year Change | -97.04% |
| 5 Year Change | -96.25% |
| Change since IPO | -96.78% |
Recent News & Updates
Recent updates
Yourgene Health Plc (LON:YGEN) Shares Could Be 34% Above Their Intrinsic Value Estimate
Sep 22
Is There An Opportunity With Yourgene Health Plc's (LON:YGEN) 35% Undervaluation?
Apr 15We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Yourgene Health Plc's (LON:YGEN) CEO For Now
Sep 22Estimating The Intrinsic Value Of Yourgene Health Plc (LON:YGEN)
Aug 07Does This Valuation Of Yourgene Health Plc (LON:YGEN) Imply Investors Are Overpaying?
Feb 25What Did Yourgene Health's (LON:YGEN) CEO Take Home Last Year?
Jan 27What Kind Of Shareholders Hold The Majority In Yourgene Health Plc's (LON:YGEN) Shares?
Dec 22Shareholder Returns
| YGEN | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 1.0% | 3.5% | 1.0% |
| 1Y | -90.9% | -6.5% | 9.5% |
Return vs Industry: YGEN underperformed the UK Medical Equipment industry which returned -7.4% over the past year.
Return vs Market: YGEN underperformed the UK Market which returned -1.4% over the past year.
Price Volatility
| YGEN volatility | |
|---|---|
| YGEN Average Weekly Movement | 40.2% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: YGEN's share price has been volatile over the past 3 months.
Volatility Over Time: YGEN's weekly volatility has increased from 25% to 40% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 253 | Lyn Rees | www.yourgene-health.com |
Yourgene Health Plc, a molecular diagnostic company, researches, develops, and commercializes gene analysis techniques for prenatal screening and other applications in the United Kingdom, rest of Europe, and internationally. It develops in vitro diagnostic products, such as IONA Test, a non-invasive pre-natal test (NIPT) for Down’s syndrome, Edwards' syndrome, and Patau’s Syndrome in pregnant women; Cystic Fibrosis Screening tests; Rapid Aneuploidy Analysis, a confirmatory diagnostic test carried out after amniocentesi; and Recurrent Pregnancy Loss, a PCR assay for the routine diagnosis of the six most common chromosomes related to pregnancy loss, as well as DPYD genotyping products. The company also offers Ranger, a technology platform for sample size selection and enrichment; Elucigene DPYD assay, a PCR test to predict a patient’s response to a chemotherapy treatment; and Clarigene SARS-CoV-2 CE-IVD, a PCR assay used for routine COVID-19 testing.
Yourgene Health Plc Fundamentals Summary
| YGEN fundamental statistics | |
|---|---|
| Market cap | UK£16.45m |
| Earnings (TTM) | -UK£8.17m |
| Revenue (TTM) | UK£29.67m |
0.6x
P/S Ratio-2.0x
P/E RatioIs YGEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YGEN income statement (TTM) | |
|---|---|
| Revenue | UK£29.67m |
| Cost of Revenue | UK£13.21m |
| Gross Profit | UK£16.46m |
| Other Expenses | UK£24.63m |
| Earnings | -UK£8.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0026 |
| Gross Margin | 55.48% |
| Net Profit Margin | -27.55% |
| Debt/Equity Ratio | 15.7% |
How did YGEN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/08 19:08 |
| End of Day Share Price | 2023/09/08 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2022/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Yourgene Health Plc is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Cavendish |
| Mark Brewer | Cavendish |
| Martin Hall | Hardman & Co. |